Editas Medicine, Inc. (EDIT) Stock Forecast
EDIT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.23 / 5 from 13 analysts
- Price target
- $6.10 average of analyst targets
- Upside to target
- +159.6% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.21
- 52-week range
- $1.67 – $4.14
EDIT analyst ratings
13 analystsNumber of analysts at each rating.
EDIT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EDIT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.25 | −$0.19 | −$0.28 | +26.4% | 7 |
| Current fiscal year (2026) | −$0.83 | −$0.99 | −$0.66 | −$1.80 | +53.9% | 7 |
| Next fiscal year (2027) | −$0.75 | −$0.85 | −$0.60 | −$0.83 | +9.2% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EDIT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.5M | $500,000 | $12.0M | −39.9% | 12 |
| Current fiscal year (2026) | $25.8M | $16.7M | $38.9M | −36.3% | 12 |
| Next fiscal year (2027) | $19.5M | $2.0M | $39.3M | −24.6% | 12 |
EDIT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EDIT revenue: reported and forecast
EDIT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.27 | −$0.28 | −$0.28 | −$0.28 | −$0.21 | −24.1% | 6 up · 0 down |
| Current fiscal year (2026) | −$0.99 | −$1.00 | −$1.00 | −$0.99 | −$0.83 | −16.2% | 5 up · 1 down |
| Next fiscal year (2027) | −$0.91 | −$0.94 | −$0.94 | −$0.96 | −$0.75 | −16.9% | 5 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EDIT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EDIT beat in 7 of 12.
What analysts expect from EDIT
13 analysts cover Editas Medicine; their consensus rating is buy (4.23 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.10, 159.6% above the latest close of $2.35. Analysts expect earnings of −$0.83 per share for 2026, +53.9% from a year earlier. For 2027 the average estimate is −$0.75 per share on revenue of $19.5 million. Editas Medicine beat the EPS estimate in 7 of the last 12 quarters.
Related: EDIT income statement, EDIT key metrics, EDIT chart. See the EDIT stock overview for the latest quote and news.
EDIT forecast FAQ
What is Editas Medicine's price target?
The average analyst price target for Editas Medicine is $6.10, 159.6% above the latest close of $2.35.
Is Editas Medicine a buy, hold or sell?
Of 13 analysts covering Editas Medicine, 9 rate it a strong buy, 0 a buy, 2 a hold, 2 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Editas Medicine's EPS forecast?
Analysts forecast −$0.83 per share for 2026 (range −$0.99 to −$0.66); for 2027 the estimate is −$0.75.
What is Editas Medicine's revenue forecast?
The average revenue estimate for 2026 is $25.8 million, growth of −36.3%; for 2027 it is $19.5 million.
When does Editas Medicine report earnings?
Editas Medicine is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.21.
Does Editas Medicine usually beat earnings estimates?
Editas Medicine reported EPS at or above the analyst estimate in 7 of the last 12 quarters.